Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

Rhea-AI Summary

Jupiter Neurosciences (NASDAQ: JUNS) was invited as the sole company to present progress at a private investor dinner on February 25, 2026 at Mar-a-Lago in Palm Beach. Management will update attendees on Phase IIa Parkinson’s progress, the neuroinflammation pipeline, and commercial execution of Nugevia™.

The event is invitation-only for accredited investors, organized by the Money Channel NYC, and management said it intends to continue direct investor engagement; contact ir@jupiterneurosciences.com for meeting requests.

News Market Reaction – JUNS

+0.87%

3 alerts

+0.87% News Effect

+$177K Valuation Impact

$21M Market Cap

1K Volume

On the day this news was published, JUNS gained 0.87%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $177K to the company's valuation, bringing the market cap to $21M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Share price: $0.5975 Daily move: 14.9% 52-week high: $3.33 +5 more

8 metrics

Share price $0.5975 Pre-news current price for JUNS

Daily move 14.9% Pre-news 24h price change

52-week high $3.33 52-week trading range high

52-week low $0.48 52-week trading range low

SEPA capacity $20.0M Standby Equity Purchase Agreement with Yorkville

Prepaid advances $6.0M Convertible notes under Yorkville financing

Q3 2025 net loss $2,288,034 Quarter ended September 30, 2025

Cash balance $723,797 Cash as of September 30, 2025

Market Reality Check

Price: $0.6027 Vol: Volume 117,733 is below t...

low vol

$0.6027 Last Close

Volume Volume 117,733 is below the 20-day average of 701,380, suggesting limited pre-news trading interest. low

Technical Shares at $0.5975 are trading below the 200-day MA of $1.20, reflecting a longer-term downtrend before this update.

Peers on Argus

JUNS showed a 14.9% pre-news gain while momentum peers were mixed, with one biot...

1 Up 1 Down

JUNS showed a 14.9% pre-news gain while momentum peers were mixed, with one biotech peer up and one down, indicating stock-specific factors rather than a broad sector move.

Historical Context

5 past events · Latest: Feb 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Financing amendment	Neutral	+0.0%	Amended Yorkville installment terms while keeping $6.0M core economics unchanged.
Jan 28	Commercial expansion	Positive	-23.5%	Expanded Nugevia addressable market targeting GLP-1 users and longevity segment.
Jan 27	Conference presentation	Neutral	-0.0%	Participation in DealFlow Discovery Conference with company presentation and meetings.
Dec 23	Investor webinar	Positive	-2.7%	Announced live investor webinar on JOTROL and upcoming Phase 2a Parkinson’s trial.
Dec 03	Year-in-review update	Positive	+2.5%	Outlined first-year public milestones, Nugevia launch, and Yorkville financing up to $20M.

Pattern Detected

Recent strategic and investor-relations announcements have led to mixed price reactions, with some positive corporate updates followed by negative moves and others aligning with the news tone.

Recent Company History

Over the last several months, Jupiter Neurosciences has focused on advancing its JOTROL™-based platform and commercializing the Nugevia™ line, while securing flexible financing with Yorkville for up to $20.0 million. The company highlighted FDA-cleared plans for a Phase 2a Parkinson’s trial and ongoing investor outreach via conferences and webinars. Today’s investor dinner presentation continues this pattern of active engagement around its clinical pipeline and commercial strategy.

Market Pulse Summary

This announcement highlights continued investor outreach as Jupiter discusses its Phase 2a Parkinson...

Analysis

This announcement highlights continued investor outreach as Jupiter discusses its Phase 2a Parkinson’s program, broader neuroinflammation pipeline, and Nugevia™ commercialization. Prior filings show reliance on Yorkville financing of up to $20.0M alongside a Q3 2025 net loss of $2,288,034 and cash of $723,797. Investors may focus on concrete clinical milestones, Nugevia revenue traction, and additional funding steps as key indicators of execution beyond this event.

Key Terms

phase 2a, standby equity purchase agreement, convertible notes, vwap, +2 more

6 terms

phase 2a medical

"plans for an upcoming Phase 2a Parkinson’s disease trial."

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

standby equity purchase agreement financial

"Under the Standby Equity Purchase Agreement, Jupiter may sell up to $20.0 million"

A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.

convertible notes financial

"prepaid advances via two convertible notes bearing 8% interest"

Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.

vwap financial

"priced at 97% of the lowest daily VWAP over a three-day period"

VWAP, or Volume-Weighted Average Price, is a way to find the average price of a stock throughout the trading day, giving more importance to times when more shares are traded. It helps traders see the typical price and decide whether a stock is expensive or cheap compared to its average, similar to finding the average speed during a trip by giving more weight to times when you traveled faster or slower.

beneficial ownership regulatory

"subject to a 4.99% beneficial‑ownership cap and a Nasdaq 19.99% exchange cap"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

going concern financial

"a wider loss, and a going‑concern warning."

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

AI-generated analysis. Not financial advice.

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida.

The invitation-only event will convene a select group of accredited and high net worth investors for focused discussions on emerging investment opportunities. The event is being organized by the Money Channel NYC.

Jupiter executives are expected to provide updates on the Company’s clinical progress, commercial strategy, and long-term objectives. Management intends to discuss advancement of the Phase IIa Parkinson’s program, broader development initiatives across the neuroinflammation pipeline, and continued commercial execution of Nugevia^™, the Company’s patented JOTROL^™-based resveratrol platform.

Jupiter’s strategy combines clinical development with active commercial revenue generation. The Company views direct engagement with the investment community as an ongoing part of its philosophy to remain accessible and transparent, and management expects to continue participating in investor meetings and forums over time.

Those interested in further information or in arranging future meetings with the Jupiter executive team are encouraged to contact ir@jupiterneurosciences.com.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and central nervous system disorders. The Company’s lead clinical program is advancing through a Phase IIa trial in Parkinson’s disease. Jupiter is also commercializing Nugevia^™, a consumer product built on its patented JOTROL^™ technology platform designed to enhance resveratrol bioavailability. Jupiter’s dual-path strategy combines clinical development with commercial revenue generation.

For more information, visit www.jupiterneurosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described in such statements. These statements include, but are not limited to, statements regarding clinical development, commercialization plans, capital planning, and future operating performance. Factors that could cause actual results to differ materially include clinical trial outcomes, regulatory developments, market acceptance of Nugevia, capital market conditions, Nasdaq listing requirements, and other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.

Investor Contact

Jupiter Neurosciences, Inc.
1001 North US Highway 1, Suite 504
Jupiter, FL 33477
Email: ir@jupiterneurosciences.com

Attachment

• Jupiter Neurosciences, Inc.

FAQ

What will Jupiter Neurosciences (JUNS) present at the Mar-a-Lago investor dinner on February 25, 2026?

Jupiter will present clinical and commercial progress, focusing on Phase IIa Parkinson’s and Nugevia™ updates. According to the company, management plans to cover advancement of the Phase IIa Parkinson’s program, broader neuroinflammation development initiatives, and continued commercial execution of its JOTROL-based resveratrol platform.

Why is Jupiter Neurosciences (JUNS) attending an invitation-only investor dinner at Mar-a-Lago?

Jupiter is attending to engage accredited investors directly and discuss strategic progress and opportunities. According to the company, the invitation-only event convenes select high net worth investors for focused discussions on clinical progress, commercial strategy, and long-term objectives.

Does the Mar-a-Lago presentation affect Jupiter Neurosciences (JUNS) clinical timelines or data releases?

The company intends to provide updates but did not state changes to formal clinical timelines or data release schedules. According to the company, management will discuss program advancement and strategy without specifying new regulatory dates or trial readout timing in this announcement.

How can investors request meetings with Jupiter Neurosciences (JUNS) management after the February 25, 2026 event?

Investors can contact Jupiter’s investor relations team via email to arrange future meetings. According to the company, those interested should email ir@jupiterneurosciences.com to request additional information or to schedule meetings with the executive team.

Who organized the investor dinner where Jupiter Neurosciences (JUNS) presented at Mar-a-Lago on February 25, 2026?

The investor dinner was organized by the Money Channel NYC and hosted at The Mar-a-Lago Club. According to the company, the event was an invitation-only gathering of accredited and high net worth investors for focused investment discussions.